# A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

> **NCT06619678** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MK-8507
- **DRUG:** Islatravir

## Key facts

- **NCT ID:** NCT06619678
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-17
- **Primary completion:** 2024-06-23
- **Final completion:** 2024-06-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619678, "A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06619678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*